4. malaria
DESCRIPTION
bahan kuliah fk unsriTRANSCRIPT
MALARIA
1
Dr. H. Harun Hudari, SpPD, FINASIM
Divisi Penyakit Tropik Infeksi
Bagian Ilmu Penyakit Dalam
RS Dr. Moh. Hoesin/FK UNSRI
Batasan
Malaria : penyakit infeksi menular akut /kronis yg disebabkan oleh sporozoa dari spesies plasmodium sp dan ditularkan oleh nyamuk anopheles yg ditandai oleh demam paroksismal, menggigil, berkeringat, disertai dengan anemia, dan hepatosplenomegali
2
Latar Belakang
Morbiditas dan mortalitas malaria tinggi
Kasus klinis 300-500 juta tiap tahun
1,5 – 2,7 juta kematian
Resiko terkena malaria : 2,3 miliar, atau 41% dari jumlah pddk dunia
Menyebar lebih dari 100 negara tropis
3
Di Indonesia ; 15 juta kasus malaria/thn
30.000 diantaranya meninggal
35% pddk resiko terkena malaria
Daerah dgn kasus klinik tinggi ;
Papua, NTT, Maluku, Sulawesi Tenggara,
Kalimantan Barat, Bangka Belitung, Bengkulu dan Riau
4
Adanya resistensi thd klorokuin
Dilaporkan pd thn 1973 di Kalimantan Timur
Hampir semua propinsi resisten klorokuin dg RI – RIII
Resisten sulfadoksin pirimetamin (RI-RIII) :10 propinsi (Irja, Lampung, Jateng, Sumut, Aceh, Palu, Sulsel,DKI Jakarta, Kaltim dan Sulut)
Resistensi thd kina : 5 propinsi (Jabar, Jateng, NTT, Irja dan Kaltim)
Depkes (1997) : 1986 – 1990 kasus malaria falsiparum di Bangka,resisten klorokuin 50% dg RII
5
Distribusi Malaria :
6
** ******** **
******
** ******
**** ** **
****
****
****
**
****
**
**
****
**
****
**
******
****
****
7
Sejarah Malaria :
- Pada tahun 3000 – 4000 Sebelum Masehi terjadi di Lembah Nil dan Asia Kecil.
- Dijelaskan pada zaman Yunani Kuno tahun 400 Sebelum Masehi.
- Tahun 1880 : Charles Laveran menemukan parasit malaria dalam darah manusia.
- Tahun1897 : Ronald Ross mendemonstrasikan penularan malaria oleh nyamuk.
- Shortt dan P.C., C. Garnham menemukan hypnozoites pada tahun 1948.
8
Epidemiologi Malaria :
- 300 – 500 juta manusia di seluruh dunia terinfeksi malaria.- 120 juta kasus klinis setiap tahun.- 40% populasi dunia tinggal di wilayah dimana terjadi
transmisi endemis, terutama di Sub-sahara Afrika ( 92 negara ).
- 1,4 – 2,7 juta kematian setiap tahun, terutama anak < 5 tahun dan wanita hamil (primigravida).
- Kematian disebabkan malaria berat, gagal organ multipel, malaria serebral, anemia kronik, Acute Respiratory Distress Syndrome (ARDS) dan malaria plasental yang disebabkan Plasmodium falciparum.
9
Epidemiologi
Kejadian luar biasa telah menyerang 11 propinsi, meliputi 13 kabupaten pada 93 desa dg jumlah kasus mencapai 20000 dg kematian 74 penderita.
Case fatality rate (CFR) malaria berat yg dilaporkan dari bbrp RS berkisar 10-50%.
Daerah yg resisten thd obat malaria pd th 2000 ditemukan di 77 kabupaten, 158 kecamatan.
10
MALARIA- Penyakit yang disebabkan parasit protozoa genus Plasmodium yang ditularkan melalui gigitan nyamuk anopheles betina yang terinfeksi Plasmodium.- Penyakit klasik ditandai oleh demam tinggi periodik dari demam tipe intermiten.
- Empat spesies Plasmodium yang dapat menginfeksi manusia : * P. falciparum * P. vivax * P. ovale * P. malariae
11
Penularan :
Vektor – Nyamuk Anopheles
Transfusi darah
Transplantasi organ
Kongenital
12
Gambar Plasmodium Falciparum :
13
Plasmodium falciparum :
- Malaria yang paling berbahaya : resiko malaria serebral, gagal ginjal, Acute Respiratory Distress Syndrome , anemia berat.
- Terapi segera sangat penting.- Infeksi yang tidak diobati pada orang yang non-imun
biasanya fatal.- Bila pasien diobati dan sembuh, tidak ada resiko relaps
karena P. falciparum tidak mempunyai stadium hepar dormant ( hypnozoite ).
14
Gambar Plasmodium vivax :
Stad.cincin
Tropozoit
Schizont
Merozoit
15
Gambar Plasmodium Ovale :
Ring
Trophozoite
Schizont
Gametocyte
16
P. vivax dan P. ovale :
- Tidak mengancam jiwa seperti Pl.falciparum.- Gejala ( terutama demam) masih menonjol.- Digunakan obat yang berbeda untuk menghilangkan
parasit stadium darah dan hepar.
17
Gambar Plasmodium Malariae :
Ring stage
Gametocyte
Trophozoite
Schizont
18
Tiga stadium siklus hidup parasit malaria :
Hepar
Sel darah merah (eritrosit)
Nyamuk
19
Siklus Hidup Parasit Malaria :
20
21
Masa Inkubasi Malaria :
Berhubungan dengan stadium hepar dari parasit malaria :– P. falciparum 12 hari– P. vivax 14 hari*– P. ovale 14 hari*– P. malariae 30 hari
*dapat 8 – 10 bulan atau lebih pada beberapa strain
22
Gejala Klinis Malaria :
- Parasit stadium darah bertanggung jawab terhadap manifestasi klinis.
- Demam merupakan gejala yang paling umum.- Gejala Paroksismal siklik yang klasik :
* Stadium dingin : menggigil dan bergoyang
* Stadium panas : badan hangat, sakit kepala, muntah
* Stadium berkeringat : lemah.
- Gejala lain dapat berupa : mual, diare, nyeri otot, dan perubahan status mental.
- Merasa sehat dalam suatu periode waktu, lalu siklus berulang dengan sendirinya.
23
MALARIA– clinical syndromesChronic Disease
Chronic or Recurrent Asymptomatic
Infection
Placental Malaria
& AnemiaAnemia
InfectionDuring
Pregnancy
Developmental Disorders
Transfusions
Death
LowBirth weight
IncreasedInfant
Mortality
Acute Disease
Non-severeAcute Febrile
disease
CerebralMalaria
Death
24
25
26
27
Struktur knobs eritrosit parasit.
28
29
Fig. 2. Integration of mini-var transgenes into the IT4var3 locus.A. Schematic of a native PfEMP1 and miniPfEMP1 proteins depicting their predicted organization and topology. The top row shows a generic PfEMP1 with its protein head structure (composed of NTS, DBL1 and CIDR1 head domains, a variable number of internal domains, a TM and an ATS). The Type 3 var encodes the smallest PfEMP1 protein and lacks a CIDR1 domain (Gardner et al., 2002; Kraemer et al., 2007). The red cell membrane is indicated by two black bars, with predicted extracellular sequence to the left. The miniPfEMP1 recombinant molecule NTS-V5-GFP is depicted as residing within the intracellular space (note that the parasite vacuolar and plasma membranes have been omitted for clarity). V5, V5 epitope.B. Schematic diagram depicting Bxb1 integrase-mediated recombination of a mini-var transgene into the attB-tagged IT4var3 locus. Coding regions are indicated by their grey shading. This schematic also indicates the probe hybridization site (black bars), the human dhfr cassette, the blasticidin resistance marker (bsd cassette), ef-1a 5′ UTR, hrp3 5′ UTR, hsp86 3′ UTR, the attP site, the attB element, the neomycin resistance cassette (neo cassette), the Bxb1 integrase cassette (Integrase cassette) and the HA tag. This schematic also shows the positions of primers used to verify integration.
30
Fig. 3. Confirmation of mini-var transgene integration into the IT4var3 locus and miniPfEMP1 expression.A. PCR analysis of transfected lines was performed using the following primers: 1091 and 1094 to detect unrecombined attB sites; 1091 and 1090 to amplify the 5′ attL junction; 594 and 1094 to amplify the 3′ attR junction; and 594 and 1090 to detect unrecombined plasmid or plasmid that integrated as a concatemer. PCR product sizes are indicated. ‘P’ indicates the attP plasmid used in the generation of each line.B. Western blot of protein extracts from transgenic parasite lines expressing miniPfEMP1s. These extracts were probed with antibodies to GFP (top panel), or BiP (used as a loading control and shown on the bottom panel). The expected miniPfEMP1 product sizes are listed to the left of panel.
31
Fig. 4. Localization of miniPfEMP1 proteins in the infected RBCs by live cell fluorescence imaging.A. Characteristic fluorescence patterns observed in the miniPfEMP1-expressing parasite lines: the first row: localization to the intracellular parasite; the second row: association with the parasite membrane/PVM; the third row: export into the RBC; the fourth row: export to or near the RBC membrane. White arrowheads indicate GFP signal in lipid-enclosed vesicles in the RBC cytoplasm.B. Percentage of each fluorescence pattern observed in each miniPfEMP1-expressing parasite line, as determined by cell counts of fluorescence patterns of at least 50 infected RBC per line.
32
Fig. 5. Export of miniPfEMP1 proteins to the RBC cytoplasm. Representative fluorescence images showing the localization of miniPfEMP1-GFP fusion proteins. Parasite lines are indicated on the left. The first column of images represents GFP fluorescence, the second column BODIPY lipid staining, the third column DAPI staining of parasite DNA and the fourth column an overlay of the three images. The NTS-V5-GFP construct was confined to the parasite and other miniPfEMP1 constructs were typically exported to the RBC cytoplasm. Exported proteins had a punctate staining pattern and GFP signal generally colocalized with BODIPY-labelled structures in the RBC cytoplasm(white arrowheads).
33
Fig. 7. Ultrastructural analysis of miniPfEMP1 transport. The NTS-V5-TM-ATS-GFP or R29var-V5-GFP-TM-ATS parasite lines were analysed by immunogold EM with anti-GFP antibodies.A. NTS-V5-TM-ATS-GFP, immunogold particles were observed in association withan electron dense structure in the RBC cytoplasm.B. NTS-V5-TM-ATS-GFP localized close to the parasite plasma membrane.C. R29var-V5-GFP-TM-ATS immunogold particles were observed close to the PVM.D–H. R29varV5-GFP-TM-ATS parasites were labelled with anti-GFP, revealing miniPfEMP1 fusion proteins at the RBC surface at or near knob structures, as well as near a Maurer’s cleft in the RBC cytoplasm (H). Anti-GFP immunogold label is found at the RBC surface or in close proximity to Maurer’s clefts (H). Labelling with 10 nm immunogold was performed after cryosectioning (A to F and H) or prior to fixation with 2% glutaraldehyde (G). White arrowheads, Maurer’s clefts; black arrowheads, surface knobs of infected RBCs. Scale bars 200 nm, p parasite, rbc red blood cell cytoplasm.
MALARIA BERATMALARIA SEREBRALMALARIA DGN BILIRUBIN > 3 MG% & gagal organ lainnyaGAGAL GINJAL AKUT < 400 ml/24 jam & Kreat > 3 mg% HIPOGLIKEMI < 40 mg%SYOK SISTOLIK < 70 mmHg / Anak < 50 mmHgANEMIA BERAT HB < 5 gr% / Ht < 15%EDEMA PARU / ARDSPERDARAHAN SPONTAN / DICKEJANG BERULANGASIDOSIS Ph <7.15 , Plasma Bicarb < 15 mmol/LHAEMOGLOBINURIAHIPERPARASITEMIA > 5 %HIPERTERMIA > 40 C ( rectal)
34
Malaria serebral :
- Sindrom yang didefinisikan sebagai Koma yang tidak disebabkan oleh penyebab lain, dengan berbagai
kadar parasitemia P. falciparum.
- 1% infeksi P. falciparum berlanjut menjadi malaria serebral dan 10-20% kasus ini meninggal.
- Biasanya terjadi pada anak usia < 2 tahun.
35
Malaria serebral
36
Malaria Berat :
Anemia : - disebabkan oleh P. falciparum dan P. vivax- destruksi eritrosit yang mengandung parasit karena berkurangnya kemampuan transport oksigen.- meningkatnya kecepatan pemindahan eritrosit yang tak terinfeksi dari sirkulasi.- supresi eritropoiesis- destruksi imun eritrosit - biasanya terjadi pada usia < 2 tahun.
37
3. Respiratory Distress Syndrome (RDS) :
- suatu gambaran malaria pada anak di Afrika dan orang dewasa di Asia.
- dapat disebabkan oleh injury terhadap endotel mikrovaskuler paru dan epitel alveolar melalui mekanisme proinflamasi
- dapat disebabkan oleh gagal jantung, pemecahan parasit, atau kebutuhan respirasi yang meningkat.
- sering berhubungan dengan asidosis metabolik.
38
Acute Respiratory distress Histopatologi
Infiltrasi sel mononuklear paru, edema
39
Faktor yg menyebabkan meningkatnya insiden malaria :
1. Resistensi obat
- penggunaan salah obat anti malaria
- sedikitnya pengembangan obat anti malaria oleh perusahaan obat dan pemerintah.
2. Resistensi insektisida
- penggunaan salah insektisida dalam bidang pertanian
- pengaruh pada lingkungan
3. Faktor ekonomi
4. Kekacauan politik
5. Kurangnya infrastruktur kesehatan masyarakat
6. Kurangnya minat secara global
7. Perilaku manusia.
40
Prinsip proteksi terhadap Malaria :
1. Waspada thd resiko, masa inkubasi, dan gejala utama.
2. Hindari digigit nyamuk terutama antara senja hingga fajar.
3. Minum obat anti malaria sbg kemoprofilaksis untuk menekan infeksi bila diperlukan.
4. Mencari diagnosis dan terapi dini bila timbul demam satu minggu atau lebih setelah memasuki wilayah dimana ada resiko malaria, sampai satu tahun setelah meninggalkan wilayah tsb.
41
Proteksi Personal thd Malaria :
- Hindari wilayah / daerah malaria- Tinggal di dalam rumah dari senja sampai fajar di dalam
kamar kelambu atau kamar AC- Memakai semprot serangga di dalam kamar dan kelambu- Memakai baju lengan panjang dan celana panjang- Oleskan losion DEET pada kulit yang tidak tertutup
pakaian.- Menggunakan kelambu.
42
DEET lotion
NSN 6840-01-284-3982
• Apply a thin coat to EXPOSED skin
• One application lasts up to 12 hours
Insect Repellents For Skin And Clothing
• Individual Dynamic Absorption Kit (IDA)
• Treatment lasts for for over 50 launderings
NSN 6840-01-345-0237
NSN 6840-01-278-1336
• Aerosol spray can
• Treatment lasts through 5-6 washes
Permethrin
US Army Center for Health Promotion and Preventive Medicine
43
Faktor-faktor yang mempengaruhi pemilihan obat kemoprofilaksis malaria :
1. Tipe malaria2. Resistensi obat pada lokasi/daerah tertentu.
Indonesia termasuk wilayah dimana P. falciparum, P. vivax, dan P. malariae sudah resisten thd chloroquine.
3. Riwayat alergi atau reaksi lain terhadap obat anti malaria yang terpilih
4. Keterbatasan yang berhubungan dg pekerjaan ( misalnya mefloquine tidak dibolehkan untuk penerbang dan penyelam )
OBAT untuk kemoprofilaksis malaria primer :3. Klorokuin 4. Mefloquine (Lariam)5. Doxycycline6. Atovaquone-proguanil (Malarone)
44
ACTs (Artemisinin Combination Therapy )
for uncomplicated falciparum malaria
The following ACTs are recommended:–artemether-lumefantrine–artesunate - amodiaquine–artesunate + mefloquine–artesunate + sulfadoxine-pyrimethamine–dihydroartemisinin – piperaquine*
efficacy of ACTs depend on the efficacy of the partner medicine
The artemisinin derivatives (oral formulations) and partner medicines of ACTs should not be used as monotherapy in the treatment of uncomplicated malaria
*Update in 2009 WHO Revised Guidelines*Update in 2009 WHO Revised Guidelines
45
46
47
First line therapy of P.FALCIPARUM in adult man :
day 1 : 4 Artesunate tabs 4 Amodiaquine tabs 2 – 3 Primaquine tabs
day 2 : 4 Artesunate tabs 4 Amodiaquine tabs
day 3 : 4 Artesunate tabs 4 Amodiaquine tabs
Second line therapy of P.FALCIPARUM in adult man :
day 1 : Quinine 3 x 2 tabs Tetrasiklin / doksisiklin 4 x 1 capsule Primaquine 2-3 tabs
day 2 – 7 : Quinine 3 x 2 tabs Tetrasiklin / doksisiklin 4 x 1 capsule
48
Dosage and administration Coartem (Artemether 20 mg/Lumefantrine 120 mg) for uncomplicated
malaria falciparum
Age group Weight group Blistercolor (Day 1) (Day 2) (Day 3)
4 months to 5yrs 5 to 14 kg Yellow
1 tb R, 1 tb R, 1 tb R,
1 tb Z 1 tb Z 1 tb Z
6 to 11y 15 to 24 kg Blue2 tb R, 2 tb R, 2 tb R,
2 tb Z 2 tb Z 2 tb Z
12 to 14y 25 to 34 kg Orange3 tb R, 3 tb R, 3 tb R,
3 tb Z 3 tb Z 3 tb Z
> 14y > 34 Green4 tb R, 4 tb R, 4 tb R,
4 tb Z 4 tb Z 4 tb Z
Source: Guideline for the treatment of malaria, WHO; 200649
PENGOBATAN MALARIA BERAT
TERHADAP PARASITEMIANYA– JENIS OBAT ( ARTESUNATE, ARTEMETER, KINA )– DOSIS ( ARTEMISININ, KINA ?? ) DAN CARA PEMBERIAN– RESISTENSI PARASIT / M.I.C PARASIT– TRANSFUSI GANTI
TERHADAP KERUSAKAN ORGAN – GAGAL GINJAL ( DIALISIS )– GAGAL PERNAFASAN ( RESPIRATOR )
TERHADAP KEADAAN UMUM ( Nutrisi/ Cairan )HASIL SEKUESTRASI PARASIT/ METABOLISMENYA– OBSTRUKSI --> EDEMA SEREBRAL (GINJAL ?/HATI?)– HEMOLISIS– SLUDGING/ ROSETTE– SITOKIN
50
SPECIFIC TREATMENT SEVERE MALARIA ( Anti Malaria)
PARENTERAL
START IMMEDIATELY
DOSAGE, WEIGHT THE PATIENT
MONITORING RESPONSE
SWITCHED TO ORAL WHEN POSSIBLE
MONITORING SIDE EFFECTS
51
Dextrose 5%
Kina
Microdrips 100-200 cc
PiggyBackCairan
Maintenance
CARA PEMBERIAN
KINA PADA
MALARIA BERAT52
53
SUPPORTIVE MANAGEMENT C.M.
AIRWAYFLUID REQUIREMENT : HYDRATION / OVERHYDRATIONCONVULSION : DIAZEPAMMONITORING GCS & VITAL SIGNLAB : FBC, GLUCOSE, PAR.COUNT, CREATININE, UREUM, BLOOD GAS, URINE S.G, SODIUM, POTASSIUM.PREVENT : SHOCK, SEPTICAEMIA, ACIDOSIS, ARDS, HYPOGLYCAEMIA, ASPIRATION, BEDSORES.TREAT HYPERPYREXIAVOLUME URINE & CATHETERIZATION
54
Initial management of Severe Malaria
Clear & maintain airwayPosition semiprone or on sideWeight patient, calculate dosageStart antimalarial chemotherapyMake rapid clinical assesmentExclude or treat hypoglycaemiaAsses state of dehydrationMeasure & monitor urine output, if nes. Catheter, S.GDiagnostic smear, rapid test, other lab testPlan first 8 hrs i.v. fluid, including anti malarial, glucose, blood trasfussionConsider CVP lineIf temp. rectal > 39 C, r. clothes, tepid sp., fan, coolingLumbal puncture, to exclude meningitisAnti convulsant, anti-microbials, vit.K
55
ANTI MALARIAL THERAPY FOR S.M
ARTEMISININ :– ARTESUNATE : I.V/ I.M / – ARTEMETHER : I.M– ARTEMISININ SUPP
QUININE
QUINIDINE
CHLOROQUINE
56
RECOMMENDED DOSES OF ANTI MALARIAL DRUGS FOR TREATMENT OF
SEVERE/CEREBRAL MALARIA
i.v. 2,4 mg/kg BB pada jam 0, dan jam 12, kemudian dilanjutkan jam 24, 48 dst sampai 7 hari. Dosis total 17 – 18 mg/ 7 hari ( 1 Amp= 60 mg)
Alternatif 1,2 mg/ Kb BB dengan waktu pemberian seperti diatas
3.2 mg/kg im pada hari I dibagi 2 dosis, dilanjutkan 1.6 mg/kg/ hari. TIDAK iv (1 amp = 80 mg)
Suppositories, 10 mg/kg at 0 & 4 hr followed by 7 mg/kg at 24,36,48 & 60 hrs.
Artemeter
DRUGS SIDE EFFECTS
Artemisinin
ARTESUNATE
Neurotoxicity in animal not human
57
RECOMMENDED DOSES OF ANTI MALARIAL DRUGS FOR TREATMENT OF
SEVERE/CEREBRAL MALARIA
Hypoglycemia, chinchonism, tinnitus, hearing impairment, nausea, dysphoria, vomiting, prolonged QT interval, dysrhythmias, hypotension
20 mg of dihydrochloride salt/kg by iv infusion over 4 hr, then after loading, followed by 10 mg/kg over 4 hr every 8 hr. Patients should not received quinine or mefloquine within last 24 hr
Alternatively, 7 mg of salt/kg can be infused over a period of 30 min, followed by 10 mg salt/kg over a period of 4 hr, or
10 mg of salt/kg (500 mg for adult) by i.v infusion over 8 hr continously 3 x a day
Quinine
DRUGS SIDE EFFECTS
58
TREATMENT OF ORGAN FAILURE
ENCEPHALOPATHY/ CONVULSION
RENAL FAILURE
ACIDOSIS
HYPOGLYCAEMIA
HYPERBILIRUBINAEMIA
RESPIRATORY FAILURE
HYPOTENSION
SEPSIS
SEVERE ANAEMIA
59
Oksigenasi
Pencegahan kejang : diazepam,
luminal, largactil
Mencegah trauma/ jatuh
Mengatasi anxiety, delirium state
Penanganan insufisiensi serebral
60
PENANGANAN IKTERIK
Tidak ada yang khusus
Hati-hati hipoglikemia
Hati-hati terhadap perdarahan
Pemberian vit. K pada ikterus yang dalam/ tanda perdarahan : 10 mg/ hari selama 3 hari.
Ulangi bilirubin, SGOT/ SGPT hari ke -3
61
HYPOGLYCAEMIA ( Bl. Sugar < 40 mg% )
Coma, 20 -50 ml 50% dextrose i.v. 5 – 10 minutes ( routine is not recommended )
Infussion 10 % dextrose ( children – 5% dextrose) – beware hyponatremia
Hypoglycaemia may developed Day 1 --- 7
Pushed 50% dextrose if necessary
Glucagon injection
Via nasogastric , beware gastric distension
In peritoneal dialysis, add glucose in dialysis fluid
Somatostatin analoque octreotide (Sandostatin)
62
Exclude pre-renal/ hypovolemic
Dopamine /& dobutamine or diuretic
Dialysis early
MANAGEMENT ACUTE RENAL FAILURE
63
MANAGEMENT OF RESPIRATORY FAILURE
PRINCIPLES :
*Consider severity & cause.
*Correct pH, if < 7.1
*Maintain PaO2 : 50 - 60 torr
* Rapid Rx anti-malarial
* Consider aggravating factors :
- secreting obstructing airways
- pneumothorax
64
METABOLIC ACIDOSIS
Occur in : - acute renal failure- hypovolaemia- shock- pulmonary oedema- hyperparasitemia
Management :* Dialysis* Sod.bicarbonate if pH< 7.15, beware
of sodium overload Pulm edema* Preverable THAM tris (hydroxymethyl)- amino
methan, no sodium* Pyruvate dehydrogenase activator dichloro –
acetate
65
HYPOTENSION (algid malaria)
Causes: gram - ve bacteriaemia, MOF
Management :
1. CVP : 0 -- 5 cm H2O with crystalloid/
colloid infusion
2. I.V. Dopamine +/ dobutamine
3. Blood culture
4.Antibiotic ( Cephalosporin III)
66
GENERAL SUPPORTIVE MEASURES
Urinary catheterization should be used to monitor output
Patients should be observed for vomiting. To ensure patient’s safety, cot-sides may be required
Regular re-positioning of patient is necessary to prevent development of pressure sores
Nasogastric tube should be avoided because of the risk of aspiration
67
KemoprofilaksisTujuan : mengurangi resiko terinfeksi malaria, shg kalau terinfeksi maka gejalanya tidak terlalu berat.
Utk orang yg akan bepergian ke daerah endemis.
Dulu : kloroquin resisten
diganti : doxisiklin, 1hr sblm brkt.
selama 12 mg, dosis 2mg/kgbb.
KI: ibu hamil, anak < 8th.
68
PROTOKOL MALARIA SEREBRAL
Definisi: Infeksi parasit Plasmodium falsifarum stadium aseksual disertai penurunan kesadaran dan bukan disebabkan oleh penyakit lain. Anamnesis: Demam intermiten, menggigil, berkeringat, riwayat pergi ke daerah endemis malaria.Pemeriksaan Fisik:Hiperpireksia (suhu rektal>400C) Konjungtiva palpebra pucat, sklera ikterik, splenomegali, gangguan kesadaran, kelemahan otot tanpa kelainan neurologis.Laboratorium: Hb turun, bilirubin>3mg/dl, hiperparasitemia >5%.
Bantuan hidup dasar
Anti malaria Penyulit
Bebaskan jalan nafas.Berikan O2
atau atau
Psg IV-line CVP jk memungkinkan (CVP 8-12cmH2O)
Psg Dauer kateter (vol.urin 1ml/kg/jam)
Artesunat 2 amp (@60mg) iv pelan (2mnt), diulang 12 jam kemudian
Dilanjutkan 2amp iv/ hari sampai 5hari
Artemeter 2 amp(@80mg) im dilanjutkan 1 amp/hari sampai 5 hari.
Kina 2 ampul (@500mg) dlm 500ml D5% /NaCl0,9% selama 4jam ke-1 gtt 40/’
D5% atau NaCl selama 4jam 40 gtt/’
Kina 1 ampul dlm 500ml D5% /NaCl selama 4 jam gtt 40/’
Selanjutnya 500ml D5%/NaCl diselang-seling dg drip Kina 1 amp tiap 4 jam sampai pasien sadar (maksimal 7 hr)
T ≥38,50C Parasetamol 15mg /kgbb/kali bs diulang /4jam
Kejang Diazepam 5-10mg iv bs diulang tiap 15’ (maks 100mg/24 jam) atau phenobarbital 2x100mg im
Hb< 10 g% Transfusi PRC
GDS <70mg/dl D40% 2fls + IVFDD10
TDS< 100mmHg kristaloid 20-30cc/kgBB/jam selama 6 jam
TDS<100mmHg, MAP≤60 NaCl 500ccPasien sadar
-Kina (@500mg) 3x1 tab sampai 7 hari (dihitung mulai drip kina) -Primakuin 3 tab
Monitor :-Vital sign tiap 30 mnt-Hb dan Ht per hari-Bil. dan Cr hr I dan III-BSS tiap 6 jam
Pasien sadar-Artesunat-amodiakuin 2x4 tab-Primakuin3 tab (@15mg)
TDS<100, MAP ≤65Dobutamin 5-20mcg/kg/mnt Dopamin 5-20mcg/kgbb/mnt Epinefrin0,05-2mcg/kgbb/mnt Norepenefrin 0,05-5 mcg/kgbb/mnt
Tidak respon
69
70